Effect of somatostatin analogs on prostate volume
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Logos Medical Publishing
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: Somatostatin is an acidic peptide that has mainly inhibitory function in the endocrine system. We aimed to evaluate whether there is a dimensional change in prostate in patients with gastrointestinal neuroendocrine tumors (NET) treated with somatostatin analogues. Methods: Most of the patients were given 30 mg IM long-acting octreotide acetate at 4-week intervals for the treatment of neuroendocrine tumor. Only 1 patient received 120 mg of another long-acting somatostatin analog subcutaneously every 4 weeks. Baseline and follow-up CT studies of the patients who were under treatment with somatostatin analogs were performed. Results: A total of 15 NET patients who received somatostatin analogs were analyzed. Thirteen (86.6%) patients had reduced prostate volume after somatostatin analog use. Median reduction in the volume of prostate was 5.66 (1.97-9.60) cc with somatostatin analog use (median treatment time was 3.2, 2.8-8.6 months). Median overall survival was 34.8 months (95% CI 13.8-55.9) in all patients. It was 36.1 months (95% CI 9.5-62.7) in patients with reduced prostate volume and 21.7 (95% CI 6.9-36.5) months in those whose prostate volumes remained unchanged (p=0.14). Conclusions: Interestingly, Somatostatin analogue therapy has decreased prostate volumes in NET patients. Potential therapeutic role of somatostatin analogs in the treatment of benign prostat hyperplasia patients might be evaluated in prospective studies. © Istanbul Medeniyet University Faculty of Medicine.
Açıklama
Anahtar Kelimeler
Neuroendocrine Tumor; Prostate Gland; Somatostatin Analog; Volume
Kaynak
Medeniyet Medical Journal
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
34
Sayı
2
